nodes	percent_of_prediction	percent_of_DWPC	metapath
Cyclobenzaprine—migraine—Prednisone—prostate cancer	0.2	0.508	CpDpCtD
Cyclobenzaprine—osteoarthritis—Prednisone—prostate cancer	0.194	0.492	CpDpCtD
Cyclobenzaprine—CYP3A4—prostate cancer	0.127	1	CbGaD
Cyclobenzaprine—CYP3A4—Estradiol valerate/Dienogest—prostate cancer	0.0335	0.113	CbGbCtD
Cyclobenzaprine—CYP1A2—Flutamide—prostate cancer	0.0278	0.0936	CbGbCtD
Cyclobenzaprine—CYP2D6—Bicalutamide—prostate cancer	0.0277	0.0931	CbGbCtD
Cyclobenzaprine—CYP2D6—Abiraterone—prostate cancer	0.0229	0.0772	CbGbCtD
Cyclobenzaprine—CYP1A2—Estrone—prostate cancer	0.0201	0.0677	CbGbCtD
Cyclobenzaprine—CYP3A4—Bicalutamide—prostate cancer	0.0176	0.0592	CbGbCtD
Cyclobenzaprine—CYP3A4—Estramustine—prostate cancer	0.0163	0.055	CbGbCtD
Cyclobenzaprine—CYP3A4—Flutamide—prostate cancer	0.0146	0.0491	CbGbCtD
Cyclobenzaprine—CYP3A4—Abiraterone—prostate cancer	0.0146	0.0491	CbGbCtD
Cyclobenzaprine—CYP1A2—Conjugated Estrogens—prostate cancer	0.0132	0.0443	CbGbCtD
Cyclobenzaprine—CYP1A2—Estradiol—prostate cancer	0.0115	0.0389	CbGbCtD
Cyclobenzaprine—CYP3A4—Cabazitaxel—prostate cancer	0.0108	0.0363	CbGbCtD
Cyclobenzaprine—CYP3A4—Estrone—prostate cancer	0.0105	0.0355	CbGbCtD
Cyclobenzaprine—CYP3A4—Ethinyl Estradiol—prostate cancer	0.00939	0.0316	CbGbCtD
Cyclobenzaprine—CYP1A2—Etoposide—prostate cancer	0.00754	0.0254	CbGbCtD
Cyclobenzaprine—CYP3A4—Conjugated Estrogens—prostate cancer	0.00689	0.0232	CbGbCtD
Cyclobenzaprine—CYP3A4—Mitoxantrone—prostate cancer	0.00627	0.0211	CbGbCtD
Cyclobenzaprine—CYP3A4—Estradiol—prostate cancer	0.00605	0.0204	CbGbCtD
Cyclobenzaprine—CYP3A4—Prednisone—prostate cancer	0.0052	0.0175	CbGbCtD
Cyclobenzaprine—CYP2D6—Doxorubicin—prostate cancer	0.00424	0.0143	CbGbCtD
Cyclobenzaprine—CYP3A4—Etoposide—prostate cancer	0.00395	0.0133	CbGbCtD
Cyclobenzaprine—CYP3A4—Docetaxel—prostate cancer	0.00362	0.0122	CbGbCtD
Cyclobenzaprine—CYP3A4—Doxorubicin—prostate cancer	0.00269	0.00907	CbGbCtD
Cyclobenzaprine—CYP1A2—urine—prostate cancer	0.000475	0.225	CbGeAlD
Cyclobenzaprine—HTR2A—urine—prostate cancer	0.000371	0.176	CbGeAlD
Cyclobenzaprine—CYP3A4—urine—prostate cancer	0.000344	0.163	CbGeAlD
Cyclobenzaprine—CYP2D6—urine—prostate cancer	0.000338	0.16	CbGeAlD
Cyclobenzaprine—Dimetacrine—ACHE—prostate cancer	0.000301	0.109	CrCbGaD
Cyclobenzaprine—Carbamazepine—RALBP1—prostate cancer	0.00029	0.105	CrCbGaD
Cyclobenzaprine—Tamoxifen—SULT1A1—prostate cancer	0.000284	0.103	CrCbGaD
Cyclobenzaprine—CYP1A2—renal system—prostate cancer	0.000116	0.055	CbGeAlD
Cyclobenzaprine—HTR2A—epithelium—prostate cancer	9.79e-05	0.0464	CbGeAlD
Cyclobenzaprine—HTR2A—renal system—prostate cancer	9.08e-05	0.043	CbGeAlD
Cyclobenzaprine—Diphenhydramine—CYP2C18—prostate cancer	9.03e-05	0.0328	CrCbGaD
Cyclobenzaprine—CYP3A4—renal system—prostate cancer	8.41e-05	0.0398	CbGeAlD
Cyclobenzaprine—CYP2D6—renal system—prostate cancer	8.27e-05	0.0392	CbGeAlD
Cyclobenzaprine—Tamoxifen—ESR2—prostate cancer	7.98e-05	0.029	CrCbGaD
Cyclobenzaprine—Carbamazepine—CYP3A5—prostate cancer	7.82e-05	0.0284	CrCbGaD
Cyclobenzaprine—Imipramine—SLC22A3—prostate cancer	7.77e-05	0.0282	CrCbGaD
Cyclobenzaprine—Diphenhydramine—SLC22A1—prostate cancer	7.37e-05	0.0268	CrCbGaD
Cyclobenzaprine—Tamoxifen—CYP1B1—prostate cancer	7.27e-05	0.0264	CrCbGaD
Cyclobenzaprine—Imipramine—CYP2C18—prostate cancer	6.82e-05	0.0248	CrCbGaD
Cyclobenzaprine—Olopatadine—CYP3A4—prostate cancer	6.45e-05	0.0235	CrCbGaD
Cyclobenzaprine—Nortriptyline—CYP3A5—prostate cancer	6.44e-05	0.0234	CrCbGaD
Cyclobenzaprine—Alimemazine—CYP3A4—prostate cancer	5.89e-05	0.0214	CrCbGaD
Cyclobenzaprine—HTR2A—testis—prostate cancer	5.87e-05	0.0278	CbGeAlD
Cyclobenzaprine—Tamoxifen—CYP3A5—prostate cancer	5.79e-05	0.021	CrCbGaD
Cyclobenzaprine—Tamoxifen—CYP2A6—prostate cancer	5.61e-05	0.0204	CrCbGaD
Cyclobenzaprine—Imipramine—SLC22A1—prostate cancer	5.57e-05	0.0202	CrCbGaD
Cyclobenzaprine—CYP2D6—testis—prostate cancer	5.35e-05	0.0253	CbGeAlD
Cyclobenzaprine—Tamoxifen—CYP19A1—prostate cancer	5.34e-05	0.0194	CrCbGaD
Cyclobenzaprine—Carbamazepine—CYP2C19—prostate cancer	5.32e-05	0.0193	CrCbGaD
Cyclobenzaprine—Tamoxifen—ESR1—prostate cancer	4.91e-05	0.0179	CrCbGaD
Cyclobenzaprine—Oedema—Docetaxel—prostate cancer	4.54e-05	0.000373	CcSEcCtD
Cyclobenzaprine—Anaphylactic shock—Docetaxel—prostate cancer	4.54e-05	0.000373	CcSEcCtD
Cyclobenzaprine—Weight increased—Doxorubicin—prostate cancer	4.53e-05	0.000372	CcSEcCtD
Cyclobenzaprine—Discomfort—Capecitabine—prostate cancer	4.53e-05	0.000372	CcSEcCtD
Cyclobenzaprine—Vision blurred—Prednisone—prostate cancer	4.52e-05	0.000371	CcSEcCtD
Cyclobenzaprine—Feeling abnormal—Etoposide—prostate cancer	4.5e-05	0.00037	CcSEcCtD
Cyclobenzaprine—Diarrhoea—Mitoxantrone—prostate cancer	4.49e-05	0.000369	CcSEcCtD
Cyclobenzaprine—Dry mouth—Capecitabine—prostate cancer	4.48e-05	0.000368	CcSEcCtD
Cyclobenzaprine—Vomiting—Estradiol—prostate cancer	4.48e-05	0.000368	CcSEcCtD
Cyclobenzaprine—Agranulocytosis—Epirubicin—prostate cancer	4.48e-05	0.000368	CcSEcCtD
Cyclobenzaprine—Amitriptyline—CYP3A5—prostate cancer	4.47e-05	0.0162	CrCbGaD
Cyclobenzaprine—Gastrointestinal pain—Etoposide—prostate cancer	4.46e-05	0.000367	CcSEcCtD
Cyclobenzaprine—Shock—Docetaxel—prostate cancer	4.46e-05	0.000367	CcSEcCtD
Cyclobenzaprine—Ill-defined disorder—Prednisone—prostate cancer	4.45e-05	0.000366	CcSEcCtD
Cyclobenzaprine—Thrombocytopenia—Docetaxel—prostate cancer	4.44e-05	0.000365	CcSEcCtD
Cyclobenzaprine—Rash—Estradiol—prostate cancer	4.44e-05	0.000365	CcSEcCtD
Cyclobenzaprine—Drowsiness—Doxorubicin—prostate cancer	4.44e-05	0.000365	CcSEcCtD
Cyclobenzaprine—Dermatitis—Estradiol—prostate cancer	4.44e-05	0.000365	CcSEcCtD
Cyclobenzaprine—Confusional state—Capecitabine—prostate cancer	4.43e-05	0.000364	CcSEcCtD
Cyclobenzaprine—Tachycardia—Docetaxel—prostate cancer	4.43e-05	0.000364	CcSEcCtD
Cyclobenzaprine—Nortriptyline—CYP2E1—prostate cancer	4.42e-05	0.0161	CrCbGaD
Cyclobenzaprine—Headache—Estradiol—prostate cancer	4.41e-05	0.000363	CcSEcCtD
Cyclobenzaprine—Agitation—Prednisone—prostate cancer	4.4e-05	0.000362	CcSEcCtD
Cyclobenzaprine—Oedema—Capecitabine—prostate cancer	4.39e-05	0.000361	CcSEcCtD
Cyclobenzaprine—Nortriptyline—CYP2C19—prostate cancer	4.38e-05	0.0159	CrCbGaD
Cyclobenzaprine—Angioedema—Prednisone—prostate cancer	4.38e-05	0.00036	CcSEcCtD
Cyclobenzaprine—Neuropathy peripheral—Doxorubicin—prostate cancer	4.35e-05	0.000358	CcSEcCtD
Cyclobenzaprine—Urticaria—Etoposide—prostate cancer	4.34e-05	0.000356	CcSEcCtD
Cyclobenzaprine—Jaundice—Doxorubicin—prostate cancer	4.33e-05	0.000356	CcSEcCtD
Cyclobenzaprine—Stomatitis—Doxorubicin—prostate cancer	4.33e-05	0.000356	CcSEcCtD
Cyclobenzaprine—Anorexia—Docetaxel—prostate cancer	4.32e-05	0.000355	CcSEcCtD
Cyclobenzaprine—Malaise—Prednisone—prostate cancer	4.32e-05	0.000355	CcSEcCtD
Cyclobenzaprine—Shock—Capecitabine—prostate cancer	4.32e-05	0.000355	CcSEcCtD
Cyclobenzaprine—Abdominal pain—Etoposide—prostate cancer	4.31e-05	0.000355	CcSEcCtD
Cyclobenzaprine—Vertigo—Prednisone—prostate cancer	4.31e-05	0.000354	CcSEcCtD
Cyclobenzaprine—Hepatitis—Epirubicin—prostate cancer	4.31e-05	0.000354	CcSEcCtD
Cyclobenzaprine—Thrombocytopenia—Capecitabine—prostate cancer	4.3e-05	0.000353	CcSEcCtD
Cyclobenzaprine—Syncope—Prednisone—prostate cancer	4.3e-05	0.000353	CcSEcCtD
Cyclobenzaprine—Tachycardia—Capecitabine—prostate cancer	4.29e-05	0.000352	CcSEcCtD
Cyclobenzaprine—Hypoaesthesia—Epirubicin—prostate cancer	4.28e-05	0.000352	CcSEcCtD
Cyclobenzaprine—Pharyngitis—Epirubicin—prostate cancer	4.27e-05	0.000351	CcSEcCtD
Cyclobenzaprine—Sweating—Doxorubicin—prostate cancer	4.26e-05	0.00035	CcSEcCtD
Cyclobenzaprine—Hyperhidrosis—Capecitabine—prostate cancer	4.25e-05	0.000349	CcSEcCtD
Cyclobenzaprine—Hypotension—Docetaxel—prostate cancer	4.24e-05	0.000348	CcSEcCtD
Cyclobenzaprine—Loss of consciousness—Prednisone—prostate cancer	4.21e-05	0.000346	CcSEcCtD
Cyclobenzaprine—Anorexia—Capecitabine—prostate cancer	4.19e-05	0.000344	CcSEcCtD
Cyclobenzaprine—Nausea—Estradiol—prostate cancer	4.18e-05	0.000344	CcSEcCtD
Cyclobenzaprine—Vomiting—Mitoxantrone—prostate cancer	4.17e-05	0.000343	CcSEcCtD
Cyclobenzaprine—Convulsion—Prednisone—prostate cancer	4.15e-05	0.000341	CcSEcCtD
Cyclobenzaprine—Agranulocytosis—Doxorubicin—prostate cancer	4.14e-05	0.00034	CcSEcCtD
Cyclobenzaprine—Hypertension—Prednisone—prostate cancer	4.14e-05	0.00034	CcSEcCtD
Cyclobenzaprine—Rash—Mitoxantrone—prostate cancer	4.14e-05	0.00034	CcSEcCtD
Cyclobenzaprine—Dermatitis—Mitoxantrone—prostate cancer	4.13e-05	0.00034	CcSEcCtD
Cyclobenzaprine—Musculoskeletal discomfort—Docetaxel—prostate cancer	4.13e-05	0.00034	CcSEcCtD
Cyclobenzaprine—Trimipramine—CYP2C19—prostate cancer	4.12e-05	0.015	CrCbGaD
Cyclobenzaprine—Headache—Mitoxantrone—prostate cancer	4.11e-05	0.000338	CcSEcCtD
Cyclobenzaprine—Hypotension—Capecitabine—prostate cancer	4.1e-05	0.000337	CcSEcCtD
Cyclobenzaprine—Insomnia—Docetaxel—prostate cancer	4.1e-05	0.000337	CcSEcCtD
Cyclobenzaprine—Myalgia—Prednisone—prostate cancer	4.08e-05	0.000335	CcSEcCtD
Cyclobenzaprine—Paraesthesia—Docetaxel—prostate cancer	4.07e-05	0.000335	CcSEcCtD
Cyclobenzaprine—Anxiety—Prednisone—prostate cancer	4.07e-05	0.000334	CcSEcCtD
Cyclobenzaprine—Diphenhydramine—CYP2C19—prostate cancer	4.05e-05	0.0147	CrCbGaD
Cyclobenzaprine—Dyspnoea—Docetaxel—prostate cancer	4.04e-05	0.000332	CcSEcCtD
Cyclobenzaprine—Somnolence—Docetaxel—prostate cancer	4.03e-05	0.000331	CcSEcCtD
Cyclobenzaprine—Discomfort—Prednisone—prostate cancer	4.03e-05	0.000331	CcSEcCtD
Cyclobenzaprine—Hypersensitivity—Etoposide—prostate cancer	4.02e-05	0.000331	CcSEcCtD
Cyclobenzaprine—Tinnitus—Epirubicin—prostate cancer	4.02e-05	0.00033	CcSEcCtD
Cyclobenzaprine—Musculoskeletal discomfort—Capecitabine—prostate cancer	4e-05	0.000329	CcSEcCtD
Cyclobenzaprine—Dyspepsia—Docetaxel—prostate cancer	3.99e-05	0.000328	CcSEcCtD
Cyclobenzaprine—Hepatitis—Doxorubicin—prostate cancer	3.98e-05	0.000328	CcSEcCtD
Cyclobenzaprine—Tamoxifen—CYP2E1—prostate cancer	3.98e-05	0.0145	CrCbGaD
Cyclobenzaprine—Insomnia—Capecitabine—prostate cancer	3.97e-05	0.000326	CcSEcCtD
Cyclobenzaprine—Hypoaesthesia—Doxorubicin—prostate cancer	3.96e-05	0.000326	CcSEcCtD
Cyclobenzaprine—Pharyngitis—Doxorubicin—prostate cancer	3.95e-05	0.000325	CcSEcCtD
Cyclobenzaprine—Paraesthesia—Capecitabine—prostate cancer	3.94e-05	0.000324	CcSEcCtD
Cyclobenzaprine—Tamoxifen—CYP2C19—prostate cancer	3.94e-05	0.0143	CrCbGaD
Cyclobenzaprine—Decreased appetite—Docetaxel—prostate cancer	3.94e-05	0.000324	CcSEcCtD
Cyclobenzaprine—Doxepin—CYP2C19—prostate cancer	3.93e-05	0.0143	CrCbGaD
Cyclobenzaprine—Tamoxifen—CYP1A1—prostate cancer	3.93e-05	0.0143	CrCbGaD
Cyclobenzaprine—Asthenia—Etoposide—prostate cancer	3.92e-05	0.000322	CcSEcCtD
Cyclobenzaprine—Dyspnoea—Capecitabine—prostate cancer	3.92e-05	0.000322	CcSEcCtD
Cyclobenzaprine—Anaphylactic shock—Prednisone—prostate cancer	3.91e-05	0.000322	CcSEcCtD
Cyclobenzaprine—Oedema—Prednisone—prostate cancer	3.91e-05	0.000322	CcSEcCtD
Cyclobenzaprine—Fatigue—Docetaxel—prostate cancer	3.91e-05	0.000321	CcSEcCtD
Cyclobenzaprine—Nausea—Mitoxantrone—prostate cancer	3.9e-05	0.00032	CcSEcCtD
Cyclobenzaprine—Constipation—Docetaxel—prostate cancer	3.88e-05	0.000319	CcSEcCtD
Cyclobenzaprine—Orphenadrine—CYP2E1—prostate cancer	3.87e-05	0.0141	CrCbGaD
Cyclobenzaprine—Dyspepsia—Capecitabine—prostate cancer	3.87e-05	0.000318	CcSEcCtD
Cyclobenzaprine—Pruritus—Etoposide—prostate cancer	3.86e-05	0.000317	CcSEcCtD
Cyclobenzaprine—Shock—Prednisone—prostate cancer	3.85e-05	0.000316	CcSEcCtD
Cyclobenzaprine—Arrhythmia—Epirubicin—prostate cancer	3.85e-05	0.000316	CcSEcCtD
Cyclobenzaprine—Tachycardia—Prednisone—prostate cancer	3.82e-05	0.000314	CcSEcCtD
Cyclobenzaprine—Decreased appetite—Capecitabine—prostate cancer	3.82e-05	0.000314	CcSEcCtD
Cyclobenzaprine—Alopecia—Epirubicin—prostate cancer	3.81e-05	0.000313	CcSEcCtD
Cyclobenzaprine—Fatigue—Capecitabine—prostate cancer	3.79e-05	0.000311	CcSEcCtD
Cyclobenzaprine—Hyperhidrosis—Prednisone—prostate cancer	3.78e-05	0.000311	CcSEcCtD
Cyclobenzaprine—Constipation—Capecitabine—prostate cancer	3.76e-05	0.000309	CcSEcCtD
Cyclobenzaprine—Feeling abnormal—Docetaxel—prostate cancer	3.74e-05	0.000307	CcSEcCtD
Cyclobenzaprine—Diarrhoea—Etoposide—prostate cancer	3.73e-05	0.000307	CcSEcCtD
Cyclobenzaprine—Anorexia—Prednisone—prostate cancer	3.73e-05	0.000306	CcSEcCtD
Cyclobenzaprine—Tinnitus—Doxorubicin—prostate cancer	3.72e-05	0.000305	CcSEcCtD
Cyclobenzaprine—Gastrointestinal pain—Docetaxel—prostate cancer	3.71e-05	0.000305	CcSEcCtD
Cyclobenzaprine—Flatulence—Epirubicin—prostate cancer	3.69e-05	0.000304	CcSEcCtD
Cyclobenzaprine—Tension—Epirubicin—prostate cancer	3.68e-05	0.000302	CcSEcCtD
Cyclobenzaprine—Dysgeusia—Epirubicin—prostate cancer	3.67e-05	0.000302	CcSEcCtD
Cyclobenzaprine—Nervousness—Epirubicin—prostate cancer	3.64e-05	0.000299	CcSEcCtD
Cyclobenzaprine—Feeling abnormal—Capecitabine—prostate cancer	3.62e-05	0.000297	CcSEcCtD
Cyclobenzaprine—Dizziness—Etoposide—prostate cancer	3.61e-05	0.000297	CcSEcCtD
Cyclobenzaprine—Gastrointestinal pain—Capecitabine—prostate cancer	3.59e-05	0.000295	CcSEcCtD
Cyclobenzaprine—Abdominal pain—Docetaxel—prostate cancer	3.59e-05	0.000295	CcSEcCtD
Cyclobenzaprine—Musculoskeletal discomfort—Prednisone—prostate cancer	3.56e-05	0.000293	CcSEcCtD
Cyclobenzaprine—Arrhythmia—Doxorubicin—prostate cancer	3.56e-05	0.000293	CcSEcCtD
Cyclobenzaprine—Insomnia—Prednisone—prostate cancer	3.54e-05	0.000291	CcSEcCtD
Cyclobenzaprine—Vision blurred—Epirubicin—prostate cancer	3.53e-05	0.00029	CcSEcCtD
Cyclobenzaprine—Alopecia—Doxorubicin—prostate cancer	3.52e-05	0.000289	CcSEcCtD
Cyclobenzaprine—Paraesthesia—Prednisone—prostate cancer	3.51e-05	0.000289	CcSEcCtD
Cyclobenzaprine—Promazine—CYP2C19—prostate cancer	3.49e-05	0.0127	CrCbGaD
Cyclobenzaprine—Urticaria—Capecitabine—prostate cancer	3.49e-05	0.000287	CcSEcCtD
Cyclobenzaprine—Ill-defined disorder—Epirubicin—prostate cancer	3.48e-05	0.000286	CcSEcCtD
Cyclobenzaprine—Abdominal pain—Capecitabine—prostate cancer	3.47e-05	0.000285	CcSEcCtD
Cyclobenzaprine—Vomiting—Etoposide—prostate cancer	3.47e-05	0.000285	CcSEcCtD
Cyclobenzaprine—Agitation—Epirubicin—prostate cancer	3.45e-05	0.000283	CcSEcCtD
Cyclobenzaprine—Dyspepsia—Prednisone—prostate cancer	3.44e-05	0.000283	CcSEcCtD
Cyclobenzaprine—Rash—Etoposide—prostate cancer	3.44e-05	0.000283	CcSEcCtD
Cyclobenzaprine—Dermatitis—Etoposide—prostate cancer	3.44e-05	0.000283	CcSEcCtD
Cyclobenzaprine—Headache—Etoposide—prostate cancer	3.42e-05	0.000281	CcSEcCtD
Cyclobenzaprine—Flatulence—Doxorubicin—prostate cancer	3.42e-05	0.000281	CcSEcCtD
Cyclobenzaprine—Tension—Doxorubicin—prostate cancer	3.4e-05	0.00028	CcSEcCtD
Cyclobenzaprine—Decreased appetite—Prednisone—prostate cancer	3.4e-05	0.00028	CcSEcCtD
Cyclobenzaprine—Dysgeusia—Doxorubicin—prostate cancer	3.4e-05	0.000279	CcSEcCtD
Cyclobenzaprine—Carbamazepine—CYP3A4—prostate cancer	3.38e-05	0.0123	CrCbGaD
Cyclobenzaprine—Malaise—Epirubicin—prostate cancer	3.38e-05	0.000278	CcSEcCtD
Cyclobenzaprine—Fatigue—Prednisone—prostate cancer	3.37e-05	0.000277	CcSEcCtD
Cyclobenzaprine—Nervousness—Doxorubicin—prostate cancer	3.37e-05	0.000277	CcSEcCtD
Cyclobenzaprine—Vertigo—Epirubicin—prostate cancer	3.37e-05	0.000277	CcSEcCtD
Cyclobenzaprine—Syncope—Epirubicin—prostate cancer	3.36e-05	0.000276	CcSEcCtD
Cyclobenzaprine—Leukopenia—Epirubicin—prostate cancer	3.36e-05	0.000276	CcSEcCtD
Cyclobenzaprine—Constipation—Prednisone—prostate cancer	3.35e-05	0.000275	CcSEcCtD
Cyclobenzaprine—Hypersensitivity—Docetaxel—prostate cancer	3.34e-05	0.000275	CcSEcCtD
Cyclobenzaprine—Palpitations—Epirubicin—prostate cancer	3.31e-05	0.000272	CcSEcCtD
Cyclobenzaprine—Loss of consciousness—Epirubicin—prostate cancer	3.29e-05	0.000271	CcSEcCtD
Cyclobenzaprine—Vision blurred—Doxorubicin—prostate cancer	3.27e-05	0.000269	CcSEcCtD
Cyclobenzaprine—Asthenia—Docetaxel—prostate cancer	3.25e-05	0.000268	CcSEcCtD
Cyclobenzaprine—Convulsion—Epirubicin—prostate cancer	3.25e-05	0.000267	CcSEcCtD
Cyclobenzaprine—Nausea—Etoposide—prostate cancer	3.24e-05	0.000266	CcSEcCtD
Cyclobenzaprine—Hypertension—Epirubicin—prostate cancer	3.24e-05	0.000266	CcSEcCtD
Cyclobenzaprine—Hypersensitivity—Capecitabine—prostate cancer	3.24e-05	0.000266	CcSEcCtD
Cyclobenzaprine—Feeling abnormal—Prednisone—prostate cancer	3.22e-05	0.000265	CcSEcCtD
Cyclobenzaprine—Ill-defined disorder—Doxorubicin—prostate cancer	3.22e-05	0.000265	CcSEcCtD
Cyclobenzaprine—Benzphetamine—CYP3A4—prostate cancer	3.21e-05	0.0117	CrCbGaD
Cyclobenzaprine—Pruritus—Docetaxel—prostate cancer	3.21e-05	0.000264	CcSEcCtD
Cyclobenzaprine—Gastrointestinal pain—Prednisone—prostate cancer	3.2e-05	0.000263	CcSEcCtD
Cyclobenzaprine—Chest pain—Epirubicin—prostate cancer	3.19e-05	0.000262	CcSEcCtD
Cyclobenzaprine—Myalgia—Epirubicin—prostate cancer	3.19e-05	0.000262	CcSEcCtD
Cyclobenzaprine—Agitation—Doxorubicin—prostate cancer	3.19e-05	0.000262	CcSEcCtD
Cyclobenzaprine—Anxiety—Epirubicin—prostate cancer	3.18e-05	0.000261	CcSEcCtD
Cyclobenzaprine—Discomfort—Epirubicin—prostate cancer	3.15e-05	0.000259	CcSEcCtD
Cyclobenzaprine—Asthenia—Capecitabine—prostate cancer	3.15e-05	0.000259	CcSEcCtD
Cyclobenzaprine—Malaise—Doxorubicin—prostate cancer	3.13e-05	0.000257	CcSEcCtD
Cyclobenzaprine—Dry mouth—Epirubicin—prostate cancer	3.12e-05	0.000257	CcSEcCtD
Cyclobenzaprine—Vertigo—Doxorubicin—prostate cancer	3.12e-05	0.000256	CcSEcCtD
Cyclobenzaprine—Syncope—Doxorubicin—prostate cancer	3.11e-05	0.000256	CcSEcCtD
Cyclobenzaprine—Urticaria—Prednisone—prostate cancer	3.11e-05	0.000255	CcSEcCtD
Cyclobenzaprine—Pruritus—Capecitabine—prostate cancer	3.11e-05	0.000255	CcSEcCtD
Cyclobenzaprine—Leukopenia—Doxorubicin—prostate cancer	3.1e-05	0.000255	CcSEcCtD
Cyclobenzaprine—Diarrhoea—Docetaxel—prostate cancer	3.1e-05	0.000255	CcSEcCtD
Cyclobenzaprine—Abdominal pain—Prednisone—prostate cancer	3.09e-05	0.000254	CcSEcCtD
Cyclobenzaprine—Imipramine—CYP2E1—prostate cancer	3.09e-05	0.0112	CrCbGaD
Cyclobenzaprine—Confusional state—Epirubicin—prostate cancer	3.08e-05	0.000254	CcSEcCtD
Cyclobenzaprine—Amitriptyline—CYP2E1—prostate cancer	3.07e-05	0.0112	CrCbGaD
Cyclobenzaprine—Palpitations—Doxorubicin—prostate cancer	3.07e-05	0.000252	CcSEcCtD
Cyclobenzaprine—Oedema—Epirubicin—prostate cancer	3.06e-05	0.000251	CcSEcCtD
Cyclobenzaprine—Anaphylactic shock—Epirubicin—prostate cancer	3.06e-05	0.000251	CcSEcCtD
Cyclobenzaprine—Imipramine—CYP2C19—prostate cancer	3.06e-05	0.0111	CrCbGaD
Cyclobenzaprine—Loss of consciousness—Doxorubicin—prostate cancer	3.05e-05	0.000251	CcSEcCtD
Cyclobenzaprine—Amitriptyline—CYP2C19—prostate cancer	3.04e-05	0.011	CrCbGaD
Cyclobenzaprine—Shock—Epirubicin—prostate cancer	3.01e-05	0.000247	CcSEcCtD
Cyclobenzaprine—Convulsion—Doxorubicin—prostate cancer	3.01e-05	0.000247	CcSEcCtD
Cyclobenzaprine—Diarrhoea—Capecitabine—prostate cancer	3e-05	0.000247	CcSEcCtD
Cyclobenzaprine—Dizziness—Docetaxel—prostate cancer	3e-05	0.000247	CcSEcCtD
Cyclobenzaprine—Thrombocytopenia—Epirubicin—prostate cancer	3e-05	0.000246	CcSEcCtD
Cyclobenzaprine—Hypertension—Doxorubicin—prostate cancer	2.99e-05	0.000246	CcSEcCtD
Cyclobenzaprine—Tachycardia—Epirubicin—prostate cancer	2.99e-05	0.000245	CcSEcCtD
Cyclobenzaprine—Hyperhidrosis—Epirubicin—prostate cancer	2.96e-05	0.000243	CcSEcCtD
Cyclobenzaprine—Myalgia—Doxorubicin—prostate cancer	2.95e-05	0.000243	CcSEcCtD
Cyclobenzaprine—Chest pain—Doxorubicin—prostate cancer	2.95e-05	0.000243	CcSEcCtD
Cyclobenzaprine—Anxiety—Doxorubicin—prostate cancer	2.94e-05	0.000242	CcSEcCtD
Cyclobenzaprine—Discomfort—Doxorubicin—prostate cancer	2.92e-05	0.00024	CcSEcCtD
Cyclobenzaprine—Anorexia—Epirubicin—prostate cancer	2.92e-05	0.00024	CcSEcCtD
Cyclobenzaprine—Dizziness—Capecitabine—prostate cancer	2.9e-05	0.000239	CcSEcCtD
Cyclobenzaprine—Dry mouth—Doxorubicin—prostate cancer	2.89e-05	0.000237	CcSEcCtD
Cyclobenzaprine—Vomiting—Docetaxel—prostate cancer	2.88e-05	0.000237	CcSEcCtD
Cyclobenzaprine—Hypersensitivity—Prednisone—prostate cancer	2.88e-05	0.000237	CcSEcCtD
Cyclobenzaprine—Rash—Docetaxel—prostate cancer	2.86e-05	0.000235	CcSEcCtD
Cyclobenzaprine—Hypotension—Epirubicin—prostate cancer	2.86e-05	0.000235	CcSEcCtD
Cyclobenzaprine—Dermatitis—Docetaxel—prostate cancer	2.86e-05	0.000235	CcSEcCtD
Cyclobenzaprine—Confusional state—Doxorubicin—prostate cancer	2.85e-05	0.000235	CcSEcCtD
Cyclobenzaprine—Headache—Docetaxel—prostate cancer	2.84e-05	0.000234	CcSEcCtD
Cyclobenzaprine—Anaphylactic shock—Doxorubicin—prostate cancer	2.83e-05	0.000233	CcSEcCtD
Cyclobenzaprine—Oedema—Doxorubicin—prostate cancer	2.83e-05	0.000233	CcSEcCtD
Cyclobenzaprine—Asthenia—Prednisone—prostate cancer	2.81e-05	0.000231	CcSEcCtD
Cyclobenzaprine—Vomiting—Capecitabine—prostate cancer	2.79e-05	0.00023	CcSEcCtD
Cyclobenzaprine—Musculoskeletal discomfort—Epirubicin—prostate cancer	2.79e-05	0.000229	CcSEcCtD
Cyclobenzaprine—Nortriptyline—CYP3A4—prostate cancer	2.79e-05	0.0101	CrCbGaD
Cyclobenzaprine—Shock—Doxorubicin—prostate cancer	2.79e-05	0.000229	CcSEcCtD
Cyclobenzaprine—Thrombocytopenia—Doxorubicin—prostate cancer	2.77e-05	0.000228	CcSEcCtD
Cyclobenzaprine—Rash—Capecitabine—prostate cancer	2.77e-05	0.000228	CcSEcCtD
Cyclobenzaprine—Pruritus—Prednisone—prostate cancer	2.77e-05	0.000227	CcSEcCtD
Cyclobenzaprine—Insomnia—Epirubicin—prostate cancer	2.77e-05	0.000227	CcSEcCtD
Cyclobenzaprine—Dermatitis—Capecitabine—prostate cancer	2.77e-05	0.000227	CcSEcCtD
Cyclobenzaprine—Tachycardia—Doxorubicin—prostate cancer	2.76e-05	0.000227	CcSEcCtD
Cyclobenzaprine—Headache—Capecitabine—prostate cancer	2.75e-05	0.000226	CcSEcCtD
Cyclobenzaprine—Paraesthesia—Epirubicin—prostate cancer	2.75e-05	0.000226	CcSEcCtD
Cyclobenzaprine—Hyperhidrosis—Doxorubicin—prostate cancer	2.74e-05	0.000225	CcSEcCtD
Cyclobenzaprine—Dyspnoea—Epirubicin—prostate cancer	2.73e-05	0.000224	CcSEcCtD
Cyclobenzaprine—Somnolence—Epirubicin—prostate cancer	2.72e-05	0.000224	CcSEcCtD
Cyclobenzaprine—Anorexia—Doxorubicin—prostate cancer	2.7e-05	0.000222	CcSEcCtD
Cyclobenzaprine—Nausea—Docetaxel—prostate cancer	2.69e-05	0.000221	CcSEcCtD
Cyclobenzaprine—Dyspepsia—Epirubicin—prostate cancer	2.69e-05	0.000221	CcSEcCtD
Cyclobenzaprine—Diarrhoea—Prednisone—prostate cancer	2.68e-05	0.00022	CcSEcCtD
Cyclobenzaprine—Decreased appetite—Epirubicin—prostate cancer	2.66e-05	0.000219	CcSEcCtD
Cyclobenzaprine—Hypotension—Doxorubicin—prostate cancer	2.65e-05	0.000217	CcSEcCtD
Cyclobenzaprine—Fatigue—Epirubicin—prostate cancer	2.64e-05	0.000217	CcSEcCtD
Cyclobenzaprine—Trimipramine—CYP3A4—prostate cancer	2.62e-05	0.00953	CrCbGaD
Cyclobenzaprine—Constipation—Epirubicin—prostate cancer	2.62e-05	0.000215	CcSEcCtD
Cyclobenzaprine—Nausea—Capecitabine—prostate cancer	2.61e-05	0.000214	CcSEcCtD
Cyclobenzaprine—Dizziness—Prednisone—prostate cancer	2.59e-05	0.000213	CcSEcCtD
Cyclobenzaprine—Musculoskeletal discomfort—Doxorubicin—prostate cancer	2.58e-05	0.000212	CcSEcCtD
Cyclobenzaprine—Insomnia—Doxorubicin—prostate cancer	2.56e-05	0.00021	CcSEcCtD
Cyclobenzaprine—Paraesthesia—Doxorubicin—prostate cancer	2.54e-05	0.000209	CcSEcCtD
Cyclobenzaprine—Dyspnoea—Doxorubicin—prostate cancer	2.52e-05	0.000207	CcSEcCtD
Cyclobenzaprine—Feeling abnormal—Epirubicin—prostate cancer	2.52e-05	0.000207	CcSEcCtD
Cyclobenzaprine—Somnolence—Doxorubicin—prostate cancer	2.52e-05	0.000207	CcSEcCtD
Cyclobenzaprine—Tamoxifen—CYP3A4—prostate cancer	2.51e-05	0.00911	CrCbGaD
Cyclobenzaprine—Gastrointestinal pain—Epirubicin—prostate cancer	2.5e-05	0.000206	CcSEcCtD
Cyclobenzaprine—Doxepin—CYP3A4—prostate cancer	2.5e-05	0.00908	CrCbGaD
Cyclobenzaprine—Dyspepsia—Doxorubicin—prostate cancer	2.49e-05	0.000205	CcSEcCtD
Cyclobenzaprine—Vomiting—Prednisone—prostate cancer	2.49e-05	0.000204	CcSEcCtD
Cyclobenzaprine—Rash—Prednisone—prostate cancer	2.47e-05	0.000203	CcSEcCtD
Cyclobenzaprine—Dermatitis—Prednisone—prostate cancer	2.46e-05	0.000203	CcSEcCtD
Cyclobenzaprine—Decreased appetite—Doxorubicin—prostate cancer	2.46e-05	0.000202	CcSEcCtD
Cyclobenzaprine—Headache—Prednisone—prostate cancer	2.45e-05	0.000201	CcSEcCtD
Cyclobenzaprine—Fatigue—Doxorubicin—prostate cancer	2.44e-05	0.000201	CcSEcCtD
Cyclobenzaprine—Orphenadrine—CYP3A4—prostate cancer	2.44e-05	0.00885	CrCbGaD
Cyclobenzaprine—Urticaria—Epirubicin—prostate cancer	2.43e-05	0.0002	CcSEcCtD
Cyclobenzaprine—Constipation—Doxorubicin—prostate cancer	2.42e-05	0.000199	CcSEcCtD
Cyclobenzaprine—Abdominal pain—Epirubicin—prostate cancer	2.42e-05	0.000199	CcSEcCtD
Cyclobenzaprine—Feeling abnormal—Doxorubicin—prostate cancer	2.33e-05	0.000192	CcSEcCtD
Cyclobenzaprine—Nausea—Prednisone—prostate cancer	2.32e-05	0.000191	CcSEcCtD
Cyclobenzaprine—Gastrointestinal pain—Doxorubicin—prostate cancer	2.31e-05	0.00019	CcSEcCtD
Cyclobenzaprine—Hypersensitivity—Epirubicin—prostate cancer	2.25e-05	0.000185	CcSEcCtD
Cyclobenzaprine—Urticaria—Doxorubicin—prostate cancer	2.25e-05	0.000185	CcSEcCtD
Cyclobenzaprine—Abdominal pain—Doxorubicin—prostate cancer	2.24e-05	0.000184	CcSEcCtD
Cyclobenzaprine—Promazine—CYP3A4—prostate cancer	2.22e-05	0.00807	CrCbGaD
Cyclobenzaprine—Asthenia—Epirubicin—prostate cancer	2.2e-05	0.00018	CcSEcCtD
Cyclobenzaprine—Pruritus—Epirubicin—prostate cancer	2.16e-05	0.000178	CcSEcCtD
Cyclobenzaprine—Diarrhoea—Epirubicin—prostate cancer	2.09e-05	0.000172	CcSEcCtD
Cyclobenzaprine—Hypersensitivity—Doxorubicin—prostate cancer	2.09e-05	0.000171	CcSEcCtD
Cyclobenzaprine—Asthenia—Doxorubicin—prostate cancer	2.03e-05	0.000167	CcSEcCtD
Cyclobenzaprine—Dizziness—Epirubicin—prostate cancer	2.02e-05	0.000166	CcSEcCtD
Cyclobenzaprine—Pruritus—Doxorubicin—prostate cancer	2e-05	0.000165	CcSEcCtD
Cyclobenzaprine—Vomiting—Epirubicin—prostate cancer	1.95e-05	0.00016	CcSEcCtD
Cyclobenzaprine—Imipramine—CYP3A4—prostate cancer	1.95e-05	0.00707	CrCbGaD
Cyclobenzaprine—Diarrhoea—Doxorubicin—prostate cancer	1.94e-05	0.000159	CcSEcCtD
Cyclobenzaprine—Amitriptyline—CYP3A4—prostate cancer	1.93e-05	0.00702	CrCbGaD
Cyclobenzaprine—Rash—Epirubicin—prostate cancer	1.93e-05	0.000159	CcSEcCtD
Cyclobenzaprine—Dermatitis—Epirubicin—prostate cancer	1.93e-05	0.000158	CcSEcCtD
Cyclobenzaprine—Headache—Epirubicin—prostate cancer	1.92e-05	0.000158	CcSEcCtD
Cyclobenzaprine—Dizziness—Doxorubicin—prostate cancer	1.87e-05	0.000154	CcSEcCtD
Cyclobenzaprine—Nausea—Epirubicin—prostate cancer	1.82e-05	0.000149	CcSEcCtD
Cyclobenzaprine—Vomiting—Doxorubicin—prostate cancer	1.8e-05	0.000148	CcSEcCtD
Cyclobenzaprine—Rash—Doxorubicin—prostate cancer	1.78e-05	0.000147	CcSEcCtD
Cyclobenzaprine—Dermatitis—Doxorubicin—prostate cancer	1.78e-05	0.000147	CcSEcCtD
Cyclobenzaprine—Headache—Doxorubicin—prostate cancer	1.77e-05	0.000146	CcSEcCtD
Cyclobenzaprine—Nausea—Doxorubicin—prostate cancer	1.68e-05	0.000138	CcSEcCtD
Cyclobenzaprine—CYP1A2—Metabolism—NAT2—prostate cancer	5.6e-06	0.000102	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—HSD3B2—prostate cancer	5.6e-06	0.000102	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—GSTO1—prostate cancer	5.6e-06	0.000102	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—PRKCQ—prostate cancer	5.55e-06	0.000101	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—NGFR—prostate cancer	5.55e-06	0.000101	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—NCOA3—prostate cancer	5.54e-06	0.000101	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—MAP3K7—prostate cancer	5.48e-06	9.97e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—ARG2—prostate cancer	5.47e-06	9.95e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—PHGDH—prostate cancer	5.47e-06	9.95e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—UMPS—prostate cancer	5.47e-06	9.95e-05	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism of lipids and lipoproteins—PPARA—prostate cancer	5.39e-06	9.8e-05	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—LRP2—prostate cancer	5.37e-06	9.77e-05	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—PLCB2—prostate cancer	5.37e-06	9.77e-05	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—CYP2C18—prostate cancer	5.37e-06	9.77e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—LDHB—prostate cancer	5.37e-06	9.76e-05	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—HPGDS—prostate cancer	5.29e-06	9.62e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—FGF10—prostate cancer	5.27e-06	9.59e-05	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—P4HB—prostate cancer	5.27e-06	9.59e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—CYP3A5—prostate cancer	5.27e-06	9.58e-05	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—CYP2C19—prostate cancer	5.26e-06	9.56e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—ADRB2—prostate cancer	5.22e-06	9.49e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—GPCR downstream signaling—JAK2—prostate cancer	5.15e-06	9.36e-05	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—ACHE—prostate cancer	5.13e-06	9.33e-05	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—GSTT1—prostate cancer	5.13e-06	9.33e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling by GPCR—MAP2K1—prostate cancer	5.13e-06	9.33e-05	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—SLC22A1—prostate cancer	5.13e-06	9.32e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling by GPCR—PIK3CD—prostate cancer	5.09e-06	9.26e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—VAV3—prostate cancer	5.09e-06	9.25e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—PDHA1—prostate cancer	5.09e-06	9.25e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—UCP3—prostate cancer	5.09e-06	9.25e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—TCN2—prostate cancer	5.09e-06	9.25e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—GSTA3—prostate cancer	5.09e-06	9.25e-05	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—CYP2A6—prostate cancer	5.07e-06	9.22e-05	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism of lipids and lipoproteins—CAV1—prostate cancer	5.07e-06	9.22e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—TGFBR2—prostate cancer	5.01e-06	9.12e-05	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—SULT2A1—prostate cancer	5e-06	9.09e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—ITPR1—prostate cancer	4.93e-06	8.98e-05	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—AKR1C3—prostate cancer	4.93e-06	8.97e-05	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—MED12—prostate cancer	4.91e-06	8.94e-05	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—PRKACB—prostate cancer	4.91e-06	8.93e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—GPCR downstream signaling—PIK3CB—prostate cancer	4.89e-06	8.89e-05	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—GNG5—prostate cancer	4.88e-06	8.87e-05	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—CYP17A1—prostate cancer	4.86e-06	8.83e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—HSD3B1—prostate cancer	4.85e-06	8.83e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—SLC22A3—prostate cancer	4.85e-06	8.83e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—IGF1R—prostate cancer	4.72e-06	8.58e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—GPCR downstream signaling—CXCL8—prostate cancer	4.7e-06	8.54e-05	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—NCOA3—prostate cancer	4.7e-06	8.54e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling by GPCR—JAK2—prostate cancer	4.67e-06	8.5e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—TBXAS1—prostate cancer	4.65e-06	8.46e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—GSTA4—prostate cancer	4.65e-06	8.46e-05	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—NCOA2—prostate cancer	4.63e-06	8.42e-05	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—prostate cancer	4.62e-06	8.4e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—GSTA2—prostate cancer	4.53e-06	8.25e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—LPL—prostate cancer	4.52e-06	8.23e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—GPCR downstream signaling—IL2—prostate cancer	4.49e-06	8.17e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—PDGFRB—prostate cancer	4.48e-06	8.16e-05	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—HPGDS—prostate cancer	4.48e-06	8.15e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—ABCG5—prostate cancer	4.48e-06	8.15e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—SULT1A1—prostate cancer	4.48e-06	8.15e-05	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—CYP2C19—prostate cancer	4.45e-06	8.1e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling by GPCR—PIK3CB—prostate cancer	4.44e-06	8.07e-05	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—SLC5A5—prostate cancer	4.41e-06	8.03e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—GSTA1—prostate cancer	4.37e-06	7.96e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—ITGB3—prostate cancer	4.37e-06	7.95e-05	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—ACHE—prostate cancer	4.35e-06	7.9e-05	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—GSTT1—prostate cancer	4.35e-06	7.9e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—GSTO1—prostate cancer	4.33e-06	7.87e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—NAT2—prostate cancer	4.33e-06	7.87e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—HSD3B2—prostate cancer	4.33e-06	7.87e-05	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—CYP2E1—prostate cancer	4.31e-06	7.84e-05	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—CYP2A6—prostate cancer	4.3e-06	7.81e-05	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—prostate cancer	4.28e-06	7.78e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling by GPCR—CXCL8—prostate cancer	4.27e-06	7.76e-05	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—NQO1—prostate cancer	4.26e-06	7.75e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—ERBB3—prostate cancer	4.24e-06	7.71e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—FGFR2—prostate cancer	4.23e-06	7.7e-05	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—TH—prostate cancer	4.2e-06	7.64e-05	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—AKR1C3—prostate cancer	4.18e-06	7.6e-05	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—CYP3A4—prostate cancer	4.16e-06	7.56e-05	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—PRKACB—prostate cancer	4.16e-06	7.56e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—PLCB2—prostate cancer	4.15e-06	7.54e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—LRP2—prostate cancer	4.15e-06	7.54e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—CYP2C18—prostate cancer	4.15e-06	7.54e-05	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—CYP17A1—prostate cancer	4.11e-06	7.48e-05	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—CYP1B1—prostate cancer	4.09e-06	7.43e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling by GPCR—IL2—prostate cancer	4.08e-06	7.42e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—P4HB—prostate cancer	4.07e-06	7.4e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—TERT—prostate cancer	4.06e-06	7.39e-05	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—prostate cancer	4.06e-06	7.38e-05	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—GGT1—prostate cancer	3.96e-06	7.2e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—SLC22A1—prostate cancer	3.96e-06	7.2e-05	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—NCOA2—prostate cancer	3.92e-06	7.13e-05	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—NCOA1—prostate cancer	3.9e-06	7.09e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—HIF1A—prostate cancer	3.88e-06	7.07e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—SULT2A1—prostate cancer	3.86e-06	7.01e-05	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—CYP19A1—prostate cancer	3.84e-06	6.99e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—MED12—prostate cancer	3.79e-06	6.9e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—LEP—prostate cancer	3.79e-06	6.9e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—GNG5—prostate cancer	3.76e-06	6.84e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—CAV1—prostate cancer	3.76e-06	6.83e-05	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—SLC5A5—prostate cancer	3.74e-06	6.8e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—KDR—prostate cancer	3.71e-06	6.76e-05	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—RXRA—prostate cancer	3.71e-06	6.75e-05	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—CYP2E1—prostate cancer	3.65e-06	6.64e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—NCOA3—prostate cancer	3.62e-06	6.59e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—ESR1—prostate cancer	3.62e-06	6.59e-05	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—NQO1—prostate cancer	3.61e-06	6.57e-05	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—COMT—prostate cancer	3.57e-06	6.5e-05	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—TH—prostate cancer	3.56e-06	6.47e-05	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—GSTP1—prostate cancer	3.56e-06	6.47e-05	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	3.54e-06	6.43e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—BAD—prostate cancer	3.53e-06	6.43e-05	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—CYP3A4—prostate cancer	3.52e-06	6.41e-05	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	3.5e-06	6.37e-05	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—ITPR1—prostate cancer	3.5e-06	6.36e-05	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—CYP1B1—prostate cancer	3.46e-06	6.3e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—HPGDS—prostate cancer	3.46e-06	6.29e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—CYP2C19—prostate cancer	3.44e-06	6.25e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—APC—prostate cancer	3.42e-06	6.22e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—PIK3CG—prostate cancer	3.42e-06	6.22e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—EGF—prostate cancer	3.38e-06	6.15e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—IRS1—prostate cancer	3.38e-06	6.15e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—GSTT1—prostate cancer	3.35e-06	6.1e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—ACHE—prostate cancer	3.35e-06	6.1e-05	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—GGT1—prostate cancer	3.35e-06	6.1e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—CYP2A6—prostate cancer	3.32e-06	6.03e-05	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—TYMS—prostate cancer	3.31e-06	6.01e-05	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—NCOA1—prostate cancer	3.3e-06	6.01e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—GSK3B—prostate cancer	3.28e-06	5.97e-05	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—GSTM1—prostate cancer	3.27e-06	5.94e-05	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—CYP19A1—prostate cancer	3.26e-06	5.92e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—INS—prostate cancer	3.24e-06	5.89e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—AKR1C3—prostate cancer	3.22e-06	5.87e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—PRKACB—prostate cancer	3.21e-06	5.84e-05	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—LPL—prostate cancer	3.21e-06	5.83e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—CYP17A1—prostate cancer	3.17e-06	5.77e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—CREBBP—prostate cancer	3.17e-06	5.77e-05	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—RXRA—prostate cancer	3.14e-06	5.72e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—IGF1—prostate cancer	3.13e-06	5.7e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling by GPCR—EGFR—prostate cancer	3.12e-06	5.67e-05	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—CYP1A1—prostate cancer	3.1e-06	5.63e-05	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—ERCC2—prostate cancer	3.07e-06	5.59e-05	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	3.06e-06	5.56e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—MAP2K1—prostate cancer	3.03e-06	5.51e-05	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—COMT—prostate cancer	3.03e-06	5.51e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—NCOA2—prostate cancer	3.03e-06	5.5e-05	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—GSTP1—prostate cancer	3.01e-06	5.48e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—PIK3CD—prostate cancer	3.01e-06	5.47e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—GPCR downstream signaling—PIK3CA—prostate cancer	2.98e-06	5.42e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—SERPINE1—prostate cancer	2.98e-06	5.41e-05	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—ITPR1—prostate cancer	2.96e-06	5.39e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling by GPCR—KRAS—prostate cancer	2.95e-06	5.36e-05	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism of lipids and lipoproteins—EP300—prostate cancer	2.91e-06	5.3e-05	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—MTHFR—prostate cancer	2.89e-06	5.25e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—SLC5A5—prostate cancer	2.89e-06	5.25e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—FGF2—prostate cancer	2.88e-06	5.24e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—NOS3—prostate cancer	2.84e-06	5.17e-05	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—PPARA—prostate cancer	2.83e-06	5.15e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—CYP2E1—prostate cancer	2.82e-06	5.13e-05	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—TYMS—prostate cancer	2.8e-06	5.09e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—NQO1—prostate cancer	2.79e-06	5.07e-05	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—GSTM1—prostate cancer	2.77e-06	5.04e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—JAK2—prostate cancer	2.76e-06	5.02e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—TH—prostate cancer	2.75e-06	5e-05	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—LPL—prostate cancer	2.72e-06	4.94e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling by GPCR—PIK3CA—prostate cancer	2.71e-06	4.92e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—MDM2—prostate cancer	2.7e-06	4.9e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—CYP1B1—prostate cancer	2.67e-06	4.86e-05	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—CAV1—prostate cancer	2.66e-06	4.85e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—ERBB2—prostate cancer	2.66e-06	4.83e-05	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—CYP1A1—prostate cancer	2.62e-06	4.77e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—PIK3CB—prostate cancer	2.62e-06	4.77e-05	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—ERCC2—prostate cancer	2.6e-06	4.73e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—GGT1—prostate cancer	2.59e-06	4.71e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—NCOA1—prostate cancer	2.55e-06	4.64e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—CXCL8—prostate cancer	2.52e-06	4.58e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—CYP19A1—prostate cancer	2.51e-06	4.57e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—CDKN1B—prostate cancer	2.46e-06	4.48e-05	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—MTHFR—prostate cancer	2.45e-06	4.45e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—GPCR downstream signaling—AKT1—prostate cancer	2.43e-06	4.43e-05	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—PIK3CG—prostate cancer	2.43e-06	4.41e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—RXRA—prostate cancer	2.42e-06	4.41e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—CASP3—prostate cancer	2.41e-06	4.39e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—IL2—prostate cancer	2.41e-06	4.38e-05	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—PPARA—prostate cancer	2.4e-06	4.37e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling by GPCR—IL6—prostate cancer	2.4e-06	4.36e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—CCND1—prostate cancer	2.35e-06	4.27e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—COMT—prostate cancer	2.34e-06	4.25e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—CTNNB1—prostate cancer	2.32e-06	4.23e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—GSTP1—prostate cancer	2.32e-06	4.23e-05	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—INS—prostate cancer	2.3e-06	4.18e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—ITPR1—prostate cancer	2.29e-06	4.16e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—MMP9—prostate cancer	2.28e-06	4.15e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—CDKN1A—prostate cancer	2.27e-06	4.13e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—PTEN—prostate cancer	2.27e-06	4.12e-05	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—CAV1—prostate cancer	2.26e-06	4.1e-05	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—CREBBP—prostate cancer	2.25e-06	4.09e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling by GPCR—AKT1—prostate cancer	2.21e-06	4.02e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—TYMS—prostate cancer	2.16e-06	3.93e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—EP300—prostate cancer	2.16e-06	3.93e-05	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	2.16e-06	3.92e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—GSTM1—prostate cancer	2.14e-06	3.89e-05	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—PIK3CD—prostate cancer	2.13e-06	3.88e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—SRC—prostate cancer	2.1e-06	3.82e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—LPL—prostate cancer	2.1e-06	3.81e-05	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—PIK3CG—prostate cancer	2.06e-06	3.74e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—VEGFA—prostate cancer	2.05e-06	3.72e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—STAT3—prostate cancer	2.03e-06	3.69e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—CYP1A1—prostate cancer	2.03e-06	3.68e-05	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—NOS3—prostate cancer	2.01e-06	3.66e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—ERCC2—prostate cancer	2.01e-06	3.65e-05	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—INS—prostate cancer	1.95e-06	3.54e-05	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—CREBBP—prostate cancer	1.91e-06	3.47e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—MTHFR—prostate cancer	1.89e-06	3.43e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—MYC—prostate cancer	1.88e-06	3.43e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—TGFB1—prostate cancer	1.88e-06	3.42e-05	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—PIK3CB—prostate cancer	1.86e-06	3.38e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—PPARA—prostate cancer	1.85e-06	3.37e-05	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—PTGS2—prostate cancer	1.84e-06	3.35e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—EGFR—prostate cancer	1.84e-06	3.35e-05	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—PIK3CD—prostate cancer	1.81e-06	3.29e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—CAV1—prostate cancer	1.74e-06	3.17e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—KRAS—prostate cancer	1.74e-06	3.16e-05	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—NOS3—prostate cancer	1.71e-06	3.1e-05	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—PTEN—prostate cancer	1.61e-06	2.92e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—PIK3CA—prostate cancer	1.6e-06	2.91e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—PIK3CG—prostate cancer	1.59e-06	2.89e-05	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—PIK3CB—prostate cancer	1.57e-06	2.86e-05	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—PTGS2—prostate cancer	1.56e-06	2.84e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—TP53—prostate cancer	1.55e-06	2.81e-05	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—EP300—prostate cancer	1.53e-06	2.79e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—INS—prostate cancer	1.5e-06	2.73e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—CREBBP—prostate cancer	1.47e-06	2.68e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—IL6—prostate cancer	1.42e-06	2.57e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—PIK3CD—prostate cancer	1.39e-06	2.54e-05	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—PTEN—prostate cancer	1.36e-06	2.48e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—NOS3—prostate cancer	1.32e-06	2.4e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—AKT1—prostate cancer	1.31e-06	2.38e-05	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—EP300—prostate cancer	1.3e-06	2.36e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—PIK3CB—prostate cancer	1.22e-06	2.21e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—PTGS2—prostate cancer	1.2e-06	2.19e-05	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—PIK3CA—prostate cancer	1.13e-06	2.06e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—PTEN—prostate cancer	1.05e-06	1.91e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—EP300—prostate cancer	1e-06	1.82e-05	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—PIK3CA—prostate cancer	9.6e-07	1.75e-05	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—AKT1—prostate cancer	9.26e-07	1.68e-05	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—AKT1—prostate cancer	7.84e-07	1.43e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—PIK3CA—prostate cancer	7.41e-07	1.35e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—AKT1—prostate cancer	6.05e-07	1.1e-05	CbGpPWpGaD
